{"id":32720,"date":"2020-07-30T10:33:52","date_gmt":"2020-07-30T09:33:52","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=32720"},"modified":"2023-04-29T22:05:41","modified_gmt":"2023-04-29T21:05:41","slug":"steinar-madsen","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/","title":{"rendered":"Steinar Madsen"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Steinar Madsen<\/h2>\n<h4>Medical Director at Norwegian Medicines Agency<\/h4>\n\t<p>Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg\" alt=\"Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: From biosimilar approval to biogenerics in clinical practice\n\t<\/h3>\n<ul>\n<li>Attitudes and acceptance in clinical practice<\/li>\n<li>Uptake in clinical practice<\/li>\n<li>Nor-Switch study and other clinical trials<\/li>\n<li>Switching and interchangeability<\/li>\n<\/ul>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/legemiddelverket.no\/english\" target=\"_blank\" rel=\"noopener\">https:\/\/legemiddelverket.no\/english<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/steinar-madsen-6aa448a1\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Steinar Madsen Medical Director at Norwegian Medicines Agency Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":32397,"parent":32717,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-32720","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Steinar Madsen &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Steinar Madsen &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-29T21:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/\",\"name\":\"Steinar Madsen &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg\",\"datePublished\":\"2020-07-30T09:33:52+00:00\",\"dateModified\":\"2023-04-29T21:05:41+00:00\",\"description\":\"Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars &#038; Biologics 2018 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Steinar Madsen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Steinar Madsen &#8226; BioTech Pharma Summit","description":"Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/","og_locale":"en_US","og_type":"article","og_title":"Steinar Madsen &#8226; BioTech Pharma Summit","og_description":"Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-04-29T21:05:41+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/","name":"Steinar Madsen &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg","datePublished":"2020-07-30T09:33:52+00:00","dateModified":"2023-04-29T21:05:41+00:00","description":"Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/steinar-madsen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biosimilars &#038; Biologics 2018 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/"},{"@type":"ListItem","position":3,"name":"Steinar Madsen"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=32720"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32720\/revisions"}],"predecessor-version":[{"id":38243,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32720\/revisions\/38243"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/32397"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=32720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}